Actinogen Medical (ACW) 2019年年度报告「ASX」.pdf

1、 ACTINOGEN MEDICAL LIMITED ABN 14 086 778 476 ANNUAL REPORT YEAR ENDED 30 JUNE 2019 ACTINOGEN MEDICAL LIMITED C O N T E N T S P A G E ContentsPageCorporate Directory1Chairmans Address2Corporate Governance Statement3Directors Report:Information on Directors11 Operations and Financial Review16 Remuner

2、ation Report(Audited)23Auditors Independence Declaration39Statement of Comprehensive Income40Statement of Financial Position41Statement of Cash Flows42Statement of Changes in Equity43Notes to the Financial Statements44Directors Declaration81Independent Auditors Report82Shareholder Information87 ACTI

3、NOGEN MEDICAL LIMITED C O R P O R A T E D I R EC T O R Y 1 Board of DirectorsAuditorsNon-Executive Chairman Dr Geoffrey BrookeErnst&YoungManaging Director Dr Bill KetelbeyErnst&Young BuildingNon-Executive Director Dr George Morstyn11 Mounts Bay RoadNon-Executive Director Mr Malcolm McComasPerth WA 6

4、000Company SecretaryLawyersMr Peter WebseK&L GatesLevel 25 South TowerPrincipal Place of Business/Registered Office525 Collins StreetSuite 901/Level 9Melbourne VIC 3000109 Pitt StreetSydney NSW 2000GTP Legal68 Aberdeen StreetContact DetailsNorthbridge WA 6003Telephone:02 8964 .auBankersABN 14 086 77

5、8 476National Australia Bank1232 Hay StreetShare RegisterWest Perth WA 6005Link Market ServicesLevel 12680 George StreetSydney NSW 2000Actinogen Medical Limited shares are listed on the Australia Securities Exchange(ASX).ASX Code:ACW ACTINOGEN MEDICAL LIMITED C H A I R M A N S A D D R E S S 2 Dear S

6、hareholder,It is with pleasure that I present to you this years Annual Report for the financial year ended 30 June 2019.This year has been a momentous year for Actinogen Medical.The Phase II XanADu clinical trial of 10mg of Xanamem in patients with mild dementia due to Alzheimers disease(AD)has been